DNA test could predict aspirin benefit in cancer

A simple DNA test could predict whether aspirin will improve a person's chance of surviving bowel cancer, a US study suggests.

DNA testing could be used to identify patients with the PIK3CA mutation (Photograph: Gustoimages/SPL)
DNA testing could be used to identify patients with the PIK3CA mutation (Photograph: Gustoimages/SPL)

People who carry a particular mutated gene linked to 15% to 20% of colorectal cancers saw greater benefit when taking aspirin than those without the mutation, researchers found. The mutation in the PIK3CA gene could be used as a biomarker to spot patients who are more likely to respond to aspirin, they say.

Aspirin is a candidate for adjuvant therapy beside the usual bowel cancer treatments. But colorectal cancer comprises several different diseases, and patients with particular genetic traits respond differently to aspirin.

Survival rates with aspirin are linked to the expression of one such biomarker, the enzyme PTGS2, by tumours. But the results of immunological tests for this marker varied between laboratories, researchers said. This means other biomarkers are needed to identify more consistently those patients who will respond best to aspirin.

In the study, an international team of researchers tested for the presence of the PIK3CA mutation in the DNA of 964 patients with rectal or colon cancer, and compared this with data on aspirin use after diagnosis and survival rates.

They found that patients with the PIK3CA mutation who took aspirin regularly had an 82% lower risk of dying from their cancer than those who did not take aspirin. But patients without this mutation saw no benefit from taking aspirin.

Study authors said the finding should be interpreted with caution, as there were small numbers of deaths in the study, and said it needed to be confirmed by further work.

They concluded: 'PIK3CA mutation may serve as a tumour biomarker that predicts the response to the initiation of aspirin therapy in patients with newly diagnosed colorectal cancer.'

  • NEJM 2012; 367: 1596-1606

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK have led the largest-ever NHS vaccination programme in response...

RCGP chair Professor Martin Marshall

Hand PCNs control of primary care infrastructure funding, says RCGP

CCG funding for primary care infrastructure should be handed to PCNs when the bodies...

Professor Martin Marshall and Talking General Practice logo

Podcast: RCGP chair Professor Martin Marshall

Talking General Practice speaks to RCGP chair Professor Martin Marshall.

Dr Chaand Nagpaul

In-house review not enough to stop 'unjust' GMC referrals, warns BMA

Doctors' leaders have repeated calls for a full independent review of the GMC referral...

Coronavirus

How widespread is long COVID in the UK?

Millions of people in the UK are living with long COVID. GPonline looks at the data...

COVID-19 vaccination sign

GP contract for autumn COVID-19 booster campaign due shortly

GP practices in England will be invited shortly to sign up for the COVID-19 autumn...